A detailed history of Raymond James & Associates transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Raymond James & Associates holds 12,458 shares of ABCL stock, worth $36,751. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,458
Previous 13,569 8.19%
Holding current value
$36,751
Previous $40,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$2.39 - $3.49 $2,655 - $3,877
-1,111 Reduced 8.19%
12,458 $32,000
Q2 2024

Jul 19, 2024

SELL
$2.73 - $4.73 $286 - $496
-105 Reduced 0.77%
13,569 $40,000
Q1 2024

Apr 22, 2024

BUY
$4.29 - $5.97 $5,525 - $7,689
1,288 Added 10.4%
13,674 $61,000
Q4 2023

Jan 16, 2024

SELL
$3.91 - $5.93 $14,646 - $22,213
-3,746 Reduced 23.22%
12,386 $70,000
Q3 2023

Oct 24, 2023

SELL
$4.6 - $7.95 $168,783 - $291,701
-36,692 Reduced 69.46%
16,132 $74,000
Q2 2023

Jul 25, 2023

BUY
$5.66 - $7.59 $32,211 - $43,194
5,691 Added 12.07%
52,824 $341,000
Q1 2023

Apr 14, 2023

BUY
$7.31 - $11.18 $195,498 - $298,997
26,744 Added 131.17%
47,133 $355,000
Q4 2022

Feb 08, 2023

SELL
$9.48 - $14.52 $19,680 - $30,143
-2,076 Reduced 9.24%
20,389 $206,000
Q3 2022

Oct 25, 2022

BUY
$9.2 - $13.68 $39,440 - $58,646
4,287 Added 23.58%
22,465 $222,000
Q2 2022

Aug 12, 2022

BUY
$5.72 - $10.65 $12,503 - $23,280
2,186 Added 13.67%
18,178 $194,000
Q1 2022

May 11, 2022

SELL
$7.46 - $14.14 $423,235 - $802,218
-56,734 Reduced 78.01%
15,992 $156,000
Q4 2021

Feb 08, 2022

SELL
$12.99 - $17.73 $696,588 - $950,771
-53,625 Reduced 42.44%
72,726 $1.04 Million
Q3 2021

Nov 02, 2021

BUY
$14.85 - $21.34 $110,602 - $158,940
7,448 Added 6.26%
126,351 $2.53 Million
Q2 2021

Aug 11, 2021

BUY
$20.19 - $34.17 $928,881 - $1.57 Million
46,007 Added 63.11%
118,903 $2.62 Million
Q1 2021

May 14, 2021

BUY
$23.29 - $53.2 $1.7 Million - $3.88 Million
72,896 New
72,896 $2.48 Million

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $841M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.